• Edara VV, Pinsky BA, Suthar MS, Lai L, Davis-Gardner ME, Floyd K, Flowers MW, Wrammert J, Hussaini L, Ciric CR, Bechnak S, Stephens K, Graham BS, Bayat Mokhtari E, Mudvari P, Boritz E, Creanga A, Pegu A, Derrien-Colemyn A, Henry AR, Gagne M, Douek DC, Sahoo MK, Sibai M, Solis D, Webby RJ, Jeevan T, Fabrizio TP. 2021. Infection and vaccine-induced neutralizing-antibody responses to the sars-cov-2 b.1.617 variants. N Engl J Med, 385:664-666.

  • Katoh K, Misawa K, Kuma K, Miyata T. 2002. Mafft:A novel method for rapid multiple sequence alignment based on fast fourier transform. Nucleic Acids Res, 30:3059-3066.

  • Lee I-J, Sun C-P, Wu P-Y, Lan Y-H, Wang I-H, Liu W-C, Tseng S-C, Tsung S-I, Chou Y-C, Kumari M, Chang Y-W, Chen H-F, Lin Y-S, Chen T-Y, Chiu C-W, Hsieh C-H, Chuang C-Y, Lin C-C, Cheng C-M, Lin H-T, Chen W-Y, Chiang P-C, Lee C-C, Liao JC, Wu H-C, Tao M-H. 2022. Omicron-specific mrna vaccine induced potent neutralizing antibody against omicron but not other sars-cov-2 variants. bioRxiv:2022.2001.2031.478406.

  • Li B, Deng A, Li K, Hu Y, Li Z, Shi Y, Xiong Q, Liu Z, Guo Q, Zou L, Zhang H, Zhang M, Ouyang F, Su J, Su W, Xu J, Lin H, Sun J, Peng J, Jiang H, Zhou P, Hu T, Luo M, Zhang Y, Zheng H, Xiao J, Liu T, Tan M, Che R, Zeng H, Zheng Z, Huang Y, Yu J, Yi L, Wu J, Chen J, Zhong H, Deng X, Kang M, Pybus OG, Hall M, Lythgoe KA, Li Y, Yuan J, He J, Lu J. 2022. Viral infection and transmission in a large, well-traced outbreak caused by the sars-cov-2 delta variant. Nat Commun, 13:460.

  • Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, Simmons R, Cottrell S, Roberts R, O'Doherty M, Brown K, Cameron C, Stockton D, McMenamin J, Ramsay M. 2021a. Effectiveness of the pfizer-biontech and oxford-astrazeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in england:Test negative case-control study. Bmj, 373:n1088.

  • Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, Stowe J, Tessier E, Groves N, Dabrera G, Myers R, Campbell CNJ, Amirthalingam G, Edmunds M, Zambon M, Brown KE, Hopkins S, Chand M, Ramsay M. 2021b. Effectiveness of covid-19 vaccines against the b.1.617.2 (delta) variant. N Engl J Med, 385:585-594.

  • Price MN, Dehal PS, Arkin AP. 2010. Fasttree 2——approximately maximum-likelihood trees for large alignments. PLoS One, 5:e9490.

  • Ramakrishnan MA. 2016. Determination of 50% endpoint titer using a simple formula. World J Virol, 5:85-86.

  • Suryawanshi RK, Chen IP, Ma T, Syed AM, Brazer N, Saldhi P, Simoneau CR, Ciling A, Khalid MM, Sreekumar B, Chen PY, Kumar GR, Montano M, Garcia-Knight MA, Sotomayor-Gonzalez A, Servellita V, Gliwa A, Nguyen J, Silva I, Milbes B, Kojima N, Hess V, Shacreaw M, Lopez L, Brobeck M, Turner F, Soveg FW, George AF, Fang X, Maishan M, Matthay M, Greene WC, Andino R, Spraggon L, Roan NR, Chiu CY, Doudna J, Ott M. 2022. Limited cross-variant immunity after infection with the sars-cov-2 omicron variant without vaccination. medRxiv.

  • Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, Xu W, Zhao Y, Li N, Zhang J, Liang H, Bao L, Xu Y, Ding L, Zhou W, Gao H, Liu J, Niu P, Zhao L, Zhen W, Fu H, Yu S, Zhang Z, Xu G, Li C, Lou Z, Xu M, Qin C, Wu G, Gao GF, Tan W, Yang X. 2020. Development of an inactivated vaccine candidate, bbibp-corv, with potent protection against sars-cov-2. Cell, 182:713-721.e719.

  • Wang N, Zhao D, Wang J, Zhang Y, Wang M, Gao Y, Li F, Wang J, Bu Z, Rao Z, Wang X. 2019. Architecture of african swine fever virus and implications for viral assembly. Science, 366:640-644.

  • Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z, Huang W, Xu W, Huang B, Wang H, Wang W, Zhang W, Li N, Xie Z, Ding L, You W, Zhao Y, Yang X, Liu Y, Wang Q, Huang L, Yang Y, Xu G, Luo B, Wang W, Liu P, Guo W, Yang X. 2021. Safety and immunogenicity of an inactivated sars-cov-2 vaccine, bbibp-corv:A randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis, 21:39-51.

  • Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang Y, Zhang W, Yang Y, Chen W, Gao X, You W, Wang X, Wang Z, Shi Z, Wang Y, Yang X, Zhang L, Huang L, Wang Q, Lu J, Yang Y, Guo J, Zhou W, Wan X, Wu C, Wang W, Huang S, Du J, Meng Z, Pan A, Yuan Z, Shen S, Guo W, Yang X. 2020. Effect of an inactivated vaccine against sars-cov-2 on safety and immunogenicity outcomes:Interim analysis of 2 randomized clinical trials. Jama, 324:951-960.

  • Xiang T, Wang J, Zheng X. 2022. The humoral and cellular immune evasion of sars-cov-2 omicron and sub-lineages. Virol Sin, 37:786-795.

  • Yu G, Smith DK, Zhu H, Guan Y, Lam TT-Y. 2017. Ggtree:An r package for visualization and annotation of phylogenetic trees with their covariates and other associated data. Methods in Ecology and Evolution, 8:28-36.

  • Zang J, Zhang C, Yin Y, Xu S, Qiao W, Lavillette D, Wang H, Huang Z. 2022. An mrna vaccine candidate for the sars-cov-2 omicron variant. bioRxiv:2022.2002.2007.479348.

  • Zhang NN, Zhang RR, Zhang YF, Ji K, Xiong XC, Qin QS, Gao P, Lu XS, Zhou HY, Song HF, Ying B, Qin CF. 2022. Rapid development of an updated mrna vaccine against the sars-cov-2 omicron variant. Cell Res, 32:401-403.

  • Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, Han W, Chen Z, Tang R, Yin W, Chen X, Hu Y, Liu X, Jiang C, Li J, Yang M, Song Y, Wang X, Gao Q, Zhu F. 2021. Safety, tolerability, and immunogenicity of an inactivated sars-cov-2 vaccine in healthy adults aged 18-59 years:A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis, 21:181-192.

  • Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W. 2020. A novel coronavirus from patients with pneumonia in china, 2019. N Engl J Med, 382:727-733.